{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:04:16Z","timestamp":1782345856807,"version":"3.54.5"},"reference-count":30,"publisher":"The Endocrine Society","issue":"9","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Patients with lipodystrophy have high prevalence of proteinuria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess kidney disease in patients with generalized (GLD) vs partial lipodystrophy (PLD), and the effects of metreleptin on proteinuria in patients with lipodystrophy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design, Setting, Patients, Intervention<\/jats:title>\n                  <jats:p>Prospective, open-label studies of metreleptin treatment in patients with GLD and PLD at the National Institutes of Health.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome Measures<\/jats:title>\n                  <jats:p>The 24-hour urinary albumin and protein excretion rates, estimated glomerular filtration rate (eGFR), and creatinine clearance (CrCl) were measured at baseline and during up to 24 months of metreleptin treatment. Patients with increases in medications affecting outcome measures were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, patients with GLD had significantly greater albuminuria, proteinuria, eGFR, and CrCl compared with patients with PLD. CrCl was above the normal range in 69% of patients with GLD and 39% with PLD (P = 0.02). With up to 24 months of metreleptin treatment, there were significant reductions in albuminuria and proteinuria in patients with GLD, but not in those with PLD. No changes in eGFR or CrCl were observed in patients with GLD or PLD during metreleptin treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with GLD had significantly greater proteinuria than those with PLD, which improved with metreleptin treatment. The mechanisms leading to proteinuria in lipodystrophy and improvements in proteinuria with metreleptin are not clear. Hyperfiltration was also more common in GLD vs PLD but did not change with metreleptin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2019-00200","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T09:03:21Z","timestamp":1555405401000},"page":"4169-4177","source":"Crossref","is-referenced-by-count":16,"title":["Effects of Metreleptin on Proteinuria in Patients With Lipodystrophy"],"prefix":"10.1210","volume":"104","author":[{"given":"Ho Lim","family":"Lee","sequence":"first","affiliation":[{"name":"Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryl A","family":"Waldman","sequence":"additional","affiliation":[{"name":"Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungyoung","family":"Auh","sequence":"additional","affiliation":[{"name":"Office of the Clinical Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E","family":"Balow","sequence":"additional","affiliation":[{"name":"Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine K","family":"Cochran","sequence":"additional","affiliation":[{"name":"Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Gorden","sequence":"additional","affiliation":[{"name":"Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-7382","authenticated-orcid":false,"given":"Rebecca J","family":"Brown","sequence":"additional","affiliation":[{"name":"Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"issue":"11","key":"2019080908044547700_bib1","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019080908044547700_bib2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019080908044547700_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/cen.13732","article-title":"Renal complications of lipodystrophy: a closer look at the natural history of kidney disease","volume":"89","author":"Akinci","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2019080908044547700_bib4","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2003-032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1-2","key":"2019080908044547700_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000354716","article-title":"Cosegregation of focal segmental glomerulosclerosis in a family with familial partial lipodystrophy due to a mutation in LMNA","volume":"124","author":"Thong","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"2019080908044547700_bib6","author":"Fountas"},{"issue":"4","key":"2019080908044547700_bib7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2215\/CJN.01271005","article-title":"Spectrum of renal diseases associated with extreme forms of insulin resistance","volume":"1","author":"Musso","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2019080908044547700_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1542\/peds.114.2.S2.555","article-title":"The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents","volume":"114","author":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents","year":"2004","journal-title":"Pediatrics"},{"issue":"3","key":"2019080908044547700_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"issue":"2","key":"2019080908044547700_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2019080908044547700_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S2213-8587(14)70155-X","article-title":"Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study","volume":"2","author":"DCCT\/EDIC research group","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9131","key":"2019080908044547700_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"2019080908044547700_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2337\/diabetes.47.5.793","article-title":"Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study","volume":"47","author":"Mykk\u00e4nen","year":"1998","journal-title":"Diabetes"},{"issue":"12","key":"2019080908044547700_bib14","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/ndt\/13.12.3079","article-title":"Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus","volume":"13","author":"Ekstrand","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2019080908044547700_bib15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1523-1755.2002.00507.x","article-title":"Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study","volume":"62","author":"Orchard","year":"2002","journal-title":"Kidney Int"},{"issue":"7","key":"2019080908044547700_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/BF00404074","article-title":"Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus","volume":"36","author":"Groop","year":"1993","journal-title":"Diabetologia"},{"issue":"8","key":"2019080908044547700_bib17","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin improves insulin sensitivity independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest"},{"issue":"10","key":"2019080908044547700_bib18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"issue":"7","key":"2019080908044547700_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/dom.12606","article-title":"One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes","volume":"18","author":"Vatier","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2019080908044547700_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2006-1546","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy","volume":"92","author":"Ebihara","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019080908044547700_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jacl.2014.08.008","article-title":"Plasma triglycerides predict incident albuminuria and progression of coronary artery calcification in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study","volume":"8","author":"Bjornstad","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"9","key":"2019080908044547700_bib22","first-page":"800","article-title":"Triglycerides are independently associated with albuminuria in Taiwanese Type 2 diabetic patients","volume":"35","author":"Tien","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2019080908044547700_bib23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1681\/ASN.2012050445","article-title":"Reversibility of structural and functional damage in a model of advanced diabetic nephropathy","volume":"24","author":"Pichaiwong","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2019080908044547700_bib24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1523-1755.1999.00626.x","article-title":"Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]","volume":"56","author":"Wolf","year":"1999","journal-title":"Kidney Int"},{"issue":"1","key":"2019080908044547700_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1096\/fj.04-2183fje","article-title":"Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy","volume":"19","author":"Suganami","year":"2005","journal-title":"FASEB J"},{"issue":"1","key":"2019080908044547700_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmet.2012.05.012","article-title":"Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling","volume":"16","author":"Imajo","year":"2012","journal-title":"Cell Metab"},{"issue":"1","key":"2019080908044547700_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cmet.2012.06.009","article-title":"Leptin in the liver: a toxic or beneficial mix","volume":"16","author":"Reitman","year":"2012","journal-title":"Cell Metab"},{"issue":"1-3","key":"2019080908044547700_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.regpep.2005.09.017","article-title":"Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats","volume":"132","author":"Gunduz","year":"2005","journal-title":"Regul Pept"},{"issue":"3","key":"2019080908044547700_bib29","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1210\/jc.2004-1494","article-title":"Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy","volume":"90","author":"Savage","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019080908044547700_bib30","doi-asserted-by":"crossref","first-page":"E1493","DOI":"10.1210\/jc.2014-1353","article-title":"Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy","volume":"99","author":"Christensen","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/jc.2019-00200\/28377045\/jc.2019-00200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/9\/4169\/29113516\/jc.2019-00200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T01:44:44Z","timestamp":1569375884000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/9\/4169\/5450715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2019-00200","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,4,16]]}}}